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Abstract
Interstitial lung disease (ILD) comprises a group of lung diseases principally affecting the 
pulmonary interstitium, for example, pulmonary fibrosis. Following acute lung injury 
(ALI), the fate of an injured lung progressing towards either injury resolution or pul-
monary fibrosis is dictated by hypoxia at various stages during the disease progression. 
Hypoxia that is tissue destructive at one stage of lung injury becomes beneficial at a 
different stage, with each hypoxic stage involving a different scheme of molecular path-
ways, cellular interplay and tissue remodeling. In this chapter, we provide a detailed 
account of hypoxia during the different stages of lung injury in ILDs, delineate the cellu-
lar and molecular mechanisms mediating tissue remodeling in the hypoxic lungs as well 
as the basic and clinical findings in this field with an emphasis on future therapeutics to 
modulate hypoxia to treat ILD.
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1. Introduction
Interstitial lung disease (ILD) comprises a group of lung diseases principally affecting the 
pulmonary interstitium, for example, pulmonary fibrosis [1]. An injured lung as a result of 
infection, inhalation of chemical, and other harmful substances either resolves over time or 
progresses into irreversible damage and fibrosis. Therefore, lung injury as in acute respiratory 
distress syndrome (ARDS), due to conditions like hypoxia can progress to interstitial lung dam-
age or fibrosis similar to ILD-associated pulmonary fibrosis. Yet, another important pulmonary 
pathological condition associated with hypoxia is the pulmonary arterial hypertension (PAH) 
[2]. The ARDS is a devastating clinical syndrome of acute lung injury (ALI) that affects both 
medical and surgical patients [3]. The official definition of ARDS was first published in 1994 by 
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American-European Consensus conference (AECC), according to which ARDS is characterized 
by arterial partial pressure of oxygen to fraction of inspired oxygen [PaO2/FIO2] ≤200 mm Hg 
with bilateral infiltrates on frontal chest radiograph, with no evidence of left atrial hyperten-
sion. A new entity—ALI was also introduced as a condition of less severe hypoxemia [PaO2/
FIO2] ≤300 mm Hg. Arterial hypoxemia that is refractory to treatment with supplemental oxy-
gen is a characteristic feature of acute lung injury. ALI is characterized by alveolar-capillary 
injury, inflammation with neutrophil accumulation and release of pro-inflammatory cytokines 
leading to alveolar edema [3]. Patients with ALI develop hypoxia. The term ALI was eventu-
ally removed in 2011 in the updated Berlin definition of ARDS. According to Berlin definition, 
ARDS was classified into three mutually exclusive categories based on the degree of hypox-
emia; mild (200 mm Hg < PaO2/FIO2 ≤ 300 mm Hg), moderate (100 mm Hg < PaO2/FIO2 ≤ 200 
mm Hg) and severe (PaO2/FIO2 ≤ 100 mm Hg) [4]. Hypoxia may be a consequence of ALI lead-
ing to deviation in lung function and preventing repair. Hypoxia induces destructive exuda-
tive changes within the lung parenchyma, which include the following: (1) increased alveolar 
paracellular permeability due to hypoxia disrupted alveolar epithelial cell (AEC) cytoskeleton 
and tight junction (TJ) protein organization; (2) Prolonged hypoxia induces loss of stress fibers 
such as actin (including breakdown of spectrin), internalization of TJ protein occludin and a 
decrease in zona occludens-1 (ZO-1) protein levels that are associated with trans-epithelial 
permeability; (3) reduced efficacy of AEC to clear alveolar edema fluid as a result of decreased 
expression of two major proteins, the apical epithelial sodium channel (ENaC) and the baso-
lateral Na/K-ATPase channel which are involved in transcellular sodium (Na) transport. Thus, 
hypoxia-mediated effects not only enhance alveolar edema but also impair alveolar edema 
clearance contributing to reduced alveolar gaseous exchange capacity in ALI [5].
2. Hypoxia in alveolar edema and fluid clearance in the lungs
The mechanism by which hypoxia promotes pulmonary edema is not completely understood 
and is still under scrutiny. Alveolar edema accumulation is a result of enhanced pulmonary 
vascular permeability. Vascular endothelial growth factor (VEGF) is a potent inducer of 
endothelial dysfunction and thus can play a crucial role in vascular permeability [6]. Since 
VEGF is induced in hypoxic conditions and recovery from hypoxia, its role in pulmonary 
vascular remodeling and enhanced alveolar edema is prominent [7]. The source of VEGF 
in the inflammatory milieu of lung injury includes monocytes, eosinophils and aggregated 
platelets. Research on hypoxia-induced VEGF expression as a cause for pathological condi-
tions has been carried out for more than two decades now. Studies have shown that both 
acute and chronic hypoxia induce an upregulation in the gene expression of VEGF, and its 
receptors (KDR/Flk and Flt) in the animal models of prolonged hypoxia-induced pulmonary 
hypertension [8]. In fact, the increase in the VEGF gene expression was seen as early as 2 h 
upon hypoxic challenge in isolated and perfused rat lungs while chronic hypoxia resulted in 
greater upregulation of the VEGF receptor genes. These studies also scrutinized the mecha-
nism by which hypoxia induces VEGF expression by examining the role of nitric oxide syn-
thase (NOS) and hypoxia inducible factors (HIFs) as the downstream regulators [8, 9]. Studies 
on transcriptional  regulation of VEGF by hypoxia have revealed a functional HIF-1 binding 
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site on the rat VEGF 5′-flanking region as a possible transcriptional activator of VEGF gene by 
hypoxia [9]. Further studies have shown the involvement of specific regions in 3′-untranslated 
region (UTR) of VEGF gene in the stability of VEGF mRNA induced by hypoxia [10]. This has 
led to investigation of proteins that bind to this specific region to control the posttranscrip-
tional regulation of VEGF expression. One such protein is HuR, a member of Elav-like protein 
family (Elav is a Drosophila RNA-binding protein required for neuronal differentiation). HuR 
was found to post-transcriptionally regulate VEGF expression by binding within four nucleo-
tides of a canonical nonameric instability element in the VEGF AU-rich element [10]. Thus, 
hypoxia regulates VEGF at both transcriptional and posttranscriptional levels. Transcriptional 
regulation is by the hypoxia-induced transcription factor HIF-1 which activates VEGF tran-
scription by binding to specific promoter sequences. A study exploring possible mechanisms 
involved in securing efficient translation of VEGF during hypoxic stress showed that internal 
ribosome entry site (IRES) present in the 5′-UTR of VEGF gene functions as an alternative to 
cap-dependent translation during such stressful conditions [11].
Becker et al. studied hypoxia-induced VEGF’s role in enhancing pulmonary vascular perme-
ability. They showed that ischemia/hypoxia-induced upregulation of VEGF mRNA and pro-
tein was associated with increased pulmonary vascular permeability [12]. Their study was also 
supported by several other studies which have reported an increase in vascular permeability 
due to exogenously administered VEGF in skin, muscle, GI tract and airways. In their study, 
hypoxic ischemia-enhanced VEGF expression, which was associated with increased HIF-1α pro-
tein expression and redistribution of VEGF protein to alveolar septae as demonstrated by immu-
nohistochemical staining. This distribution of VEGF protein in the alveolar septae was further 
associated with increased pulmonary vascular permeability, suggesting its role in acute lung 
injury and alveolar edema [12]. The enhanced pulmonary vascular permeability effect of VEGF 
was also confirmed by another study in a sepsis-induced lung injury model, which showed that 
enhanced plasma VEGF level was accompanied by increased expression of vascular permeabil-
ity-mediating VEGF receptor, Flt-1 and not the angiogenic-mediating receptor, Flk-1. As a result, 
enhanced lung edema was observed confirming the role of VEGF in causing alveolar edema [13].
Na,K-ATPase channels present in the alveolar epithelial cells play a major role in edema clear-
ance from the alveoli [14]. Hypoxia-induced pulmonary edema also disrupts their function 
and inhibits edema clearance. Studies have shown that hypoxia generated reactive oxygen 
species (ROS) activates PKCζ (Protein Kinase C Zeta is a key regulator of critical intracellular 
signaling pathways induced by various extracellular stimuli), which in turn, phosphorylates 
the α1-subunit of Na,K-ATPase at Ser-18 site leading to its endocytosis through a clathrin-
dependent mechanism and eventually to lysosomal degradation. With the loss of Na,K-
ATPase, edema reabsorption is impaired and thus hypoxia not only promotes pulmonary 
edema but also inhibits its clearance as observed in conditions like ALI [14].
3. Hypoxia in pulmonary aquaporin’s expression and edema
Aquaporins (AQPs) comprise a group of cell membrane water-transporting proteins that are 
involved in physiological as well as pathological fluid transport. They have been identified 
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in the lung and are believed to play a major role in pulmonary edema [15]. AQPs can bidirec-
tionally transport fluid across the alveolar epithelium and hence are involved in both edema 
formation and clearance of edema from alveoli (thus injury resolution). About 6 (AQP-1, -3, 
-4, -5, -8 and -9) of the 13 different AQPs are distributed in lung tissue, and it is very interest-
ing to study how hypoxia regulates the expression of these AQPs and thus pulmonary edema 
formation or clearance of edema. AQPs expression could play a major role in the pathological 
condition of hypoxia-induced enhanced pulmonary edema and ALI [15]. Several studies have 
scrutinized the role of aquaporins in pulmonary edema, and the results are controversial, yet 
intriguing. For example, Wu et al. studied the role of AQP-1 [expressed on pulmonary endo-
thelial cells (ECs) and alveolar type II cells] and AQP-4 (expressed throughout the airways 
epithelial cells) in relation to high-altitude hypoxia lung injury. They found that hypoxia-
induced pulmonary edema was associated with a decreased expression of AQP-1 and no 
change in the expression of AQP-4 [16]. They went on to reason that hypoxia resulted in 
pulmonary edema as a consequence of decreased function of AQP-1, which plays a regula-
tory role in water clearance around the bronchi and vessels. However, the relation of AQP-1 
expression and pulmonary edema, as a result of hypoxia was only correlative and the study 
did not use knockout models to confirm the relationship between these effects of hypoxia. On 
the contrary, Su et al. showed that depletion of AQP-1 does not affect isosmolar fluid clear-
ance and had no effect on lung edema. Nevertheless, depletion of AQP-1 resulted in a 10-fold 
decrease in the alveolar-capillary osmotic water permeability. They concluded that depletion 
of AQP-1 did not have any effect on lung edema formation and resolution [17]. Several other 
reports have also ruled out the role of AQP-1, -4 and -5 in physiological clearance of water in 
the lung or the accumulation of edema in the injured lung. Another report using gene knock-
out mouse model of AQP5 in hypoxic conditions showed a significant increase in pulmonary 
edema with the loss of AQP-5 [18]. As aforementioned, a few other reports also demonstrated 
that upregulation and downregulation of AQPs expression is related to pulmonary edema in 
different kinds of lung injuries. AQP-1 has also been shown to facilitate stabilization of HIF 
and has been speculated that besides its role as water transporter, it could also be involved in 
oxygen transport [19]. Therefore, the effect of hypoxia on AQPs expression especially in the 
lung and its effect on pulmonary edema warrants further studies before arriving at a conclu-
sion [16–20].
4. Hypoxia in pulmonary arterial hypertension (PAH)
Prolonged lung injury can lead to lung fibrosis as well as PAH. Hypoxia is a well-studied 
trigger for pulmonary vascular remodeling and PAH development [2]. In fact, hypoxia-
induced PAH is an established animal model for studying the pathophysiology and thera-
peutic management of PAH. PAH is a refractory disease characterized by uncontrolled 
vascular remodeling involving enhanced proliferation and differentiation of pulmonary 
vascular ECs and pulmonary vascular smooth muscle cells [2]. This vascular remodeling 
ensues enhanced pulmonary arterial pressure (≥25 mm Hg on right heart catheterization) 
due to increased pulmonary vasoconstriction and increased pulmonary vascular resis-
tance and eventually right ventricular failure [2]. Chronic hypoxia is a well-known trigger 
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for the abovementioned events. The mechanism by which hypoxia induces PAH has been 
extensively studied and involves several molecular signaling pathways. Leptin, a non-gly-
cosylated protein, synthesized and secreted by adipocytes is encoded by obese (ob) gene, 
which is hypoxia sensitive. HIF-1 induces the expression of ob gene in adipocytes, and 
clinical studies have suggested an association between plasma leptin levels and severity 
of PAH [21]. Results of studies scrutinizing the role of leptin signaling in hypoxia-induced 
PAH show that hypoxia-induced leptin expression results in pulmonary arterial smooth 
muscle cells (PASMCs) proliferation through ERK, STAT and AKT pathways [21]. These 
results were further confirmed in ob/ob mice. Obese gene knockout mice subjected to 
hypoxia showed an attenuated hypoxia-induced PAH that was gauged in terms of reduced 
right ventricular systolic pressure (RVSP) and right ventricular hypertrophy index (RVHI) 
when compared to wild-type (WT) mice. Thus, leptin signaling could be a potential thera-
peutic target to treat hypoxia-induced PAH [21]. In hypoxia-induced pulmonary hyperten-
sion, iron supplementation has been found to be beneficial [22]. A study involving human 
subjects in an acute model of mountain sickness has shown that iron supplementation was 
associated with a decrease in pulmonary arterial systolic pressure (PASP) while progres-
sive development of iron deficiency correlated with worsening of pulmonary arterial pres-
sure determined by echocardiography, thus suggesting a causal relationship between iron 
deficiency and acute hypoxic PAH [23]. Recent studies speculate that iron deficiency may 
worsen hypoxic pulmonary hypertension through HIFs signaling [24].
HIFs are transcription factors comprising of an O
2
-sensitive α-subunit, mainly HIF-1α and 
HIF-2α and a constitutively expressed β-subunit which are responsible for mediating adap-
tive responses to hypoxia and ischemia [25]. HIF-α and HIF-β form heterodimer and induce 
the transcription of over 100 genes that affect cellular functions ranging from metabolism, 
survival, proliferation, migration and angiogenesis among several others [25]. While HIF-1α 
is more ubiquitously expressed, HIF-2α expression is predominant in the lung tissue [25]. 
Several studies have shown the mechanistic role of HIF-2α in hypoxia-induced PAH. In 
hypoxia-induced PAH studies, even partial deficiency of either HIF1α (HIF1α+/−) or HIF2α 
(HIF2α+/−), achieved using murine models, significantly decreased pulmonary arterial pres-
sure and right ventricular hypertrophy induced by chronic hypoxia in comparison with wild-
type mice that did not have any alteration in HIF1α or HIF2α expression [26]. The role of 
HIFs in hypoxia-induced PAH was further scrutinized and deficiency in HIFs-related ben-
eficial effects in PAH was at least partly due to the reduced pulmonary vascular remodeling 
observed in these animals. Further in vitro analysis on PASMCs showed that HIF-1-dependent 
smooth muscle hypertrophy contributed to pulmonary vascular remodeling during hypoxia 
[26]. HIF1α is involved in hypoxia-induced PASMC depolarization, reduction in K+ channel 
expression and activity and elevated intracellular calcium concentration and pH. This eventu-
ally results in altered PASMC ion homeostasis contributing to a more contractile, apoptosis 
resistant, proliferative and migratory phenotype [26]. Furthermore, in human PAH patients 
and mouse models of PAH, dysregulation of HIF pathway was reported and it has been asso-
ciated with HIF-2α mutations, which was confirmed by studies where loss of one copy of 
HIF-2α gene was sufficient to attenuate hypoxia-induced PAH in these animal models [27]. 
On the other hand, HIF-2α gain of functions is associated with PAH. Studies scrutinizing the 
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mechanism by which HIF-2α regulates hypoxic PAH have found several ways by which it 
mediates the hypoxic effects. In human PASMC, hypoxia increases expression of transcrip-
tion factor forkhead box M1 (FoxM1), through HIF-2α, to promote PASMC proliferation [27]. 
Secreted matricellular protein thrombospondin-1 (TSP-1) is believed to play an important role 
in vascular health and disease via inhibition of vasodilation in part by limiting NO production 
and signaling [28]. Vascular remodeling in PAH involves the proliferation of both pulmonary 
artery smooth muscle cells (PASMCs) and fibroblasts apart from endothelial dysfunction. In 
a recent study published from our laboratory, we showed that hypoxia-induced pulmonary 
rarefaction and fibrosis in mice lung, and mechanistically, we found that hypoxia-induced 
Akt1 expression in fibroblasts was associated with enhanced TSP-1 expression resulting 
in fibroproliferation and fibrosis [29]. Another study has shown that hypoxia, in a HIF-2α-
dependent manner, increases the expression of TSP-1 in pulmonary tissue and pulmonary 
artery cells which in turn contributes to enhanced endothelial permeability (mediated in part 
by changes in cell-cell adhesion) and accompanied by increased fibroblast and PASMC prolif-
eration which is at least partially due to restricted adhesion of these cells in their mouse model 
of hypoxia-induced PAH. Also it was speculated that TSP-1 could promote hypoxic pulmo-
nary artery contraction through enhanced TSP-1–induced endothelin-1 expression [28].
Prolyl hydroxylase domain-containing enzymes (PHDs) use molecular O
2
 as a substrate to 
hydroxylate-specific proline residues of HIF-α which subsequently promotes HIF-α binding 
to von Hippel-Lindau (VHL protein) and ubiquitin E3 ligase, resulting in ubiquitination and 
proteasomal degradation [27]. In patients with idiopathic pulmonary fibrosis (IPF), PHD2 
expression is diminished in ECs of obliterative pulmonary vessels [27]. A study using mouse 
model of endothelial and hematopoietic cells-specific knockdown of gene encoding PHD2 
has shown that these mice spontaneously develop PAH with obliterative vascular remodel-
ing as seen in human PAH [27]. They found that PHD2 deficiency in ECs promoted HIF-
2α-mediated (and not HIF-1α) expression of CXCL12 (also known as stromal cell-derived 
factor 1α) that had a paracrine effect on PASMC proliferation contributing to the pathogenesis 
of severe PAH in this mouse model. PHD2 deficiency in ECs also promoted endothelin-1 
expression that resulted in pulmonary artery-vasoconstriction. Thus, HIF-2α-mediated vas-
cular remodeling and plexiform-like lesions formation (due to PASMC proliferation) resulted 
in PAH in this mouse model [27, 28]. As discussed above, prevention of PASMC apopto-
sis along with enhanced proliferation is an important pathological event in hypoxic PAH. 
Another study showed the mechanism by which hypoxia mediates this effect. In PASMCs, 
hypoxia induces opening of mitochondrial ATP-sensitive potassium channels (mitoKATP), which results in calcium-dependent increase in mitochondrial permeability or mitochondrial 
membrane transition (MPT). MPT eventually leads to loss of mitochondrial membrane poten-
tial (denoted by ΔΨm), thus preventing the cytochrome C release from mitochondria and 
inhibition of cytochrome C–caspase 9 pathway induced PASMC apoptosis [30]. The involve-
ment of mitoKATP channels in hypoxia-induced PASMC apoptosis resistance was further con-firmed by administering 5-hydroxydecanoate (5-HD), a compound that prevents opening of 
mitoKATP channels abolishes these effects of hypoxia to a certain extent and prevents mitoKATP channels opening and PASMC apoptosis. Hypoxia-induced opening of mitoKATP was not only associated with prevention of PASMC apoptosis but also increased the production of H
2
O
2
 in 
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mitochondria. The effect of this ROS production was an increased transcriptional activity of 
AP-1, which is responsible for the proliferation of PASMCs. Thus, hypoxia through mitoKATP opening prevented apoptosis and enhanced proliferation of PASMCs. As discussed, apart 
from proliferation of PASMCs, hypoxia-induced prevention of PASMC apoptosis also plays 
a major role in PAH. Another mechanism involves inhibition of the mitochondrial pro-apop-
totic Bax protein expression and induction of the anti-apoptotic Bcl-2 expression, thus pre-
venting the release of mitochondrial cytochrome C into cytoplasm and eventually inhibiting 
cleavage of caspase 9 resulting in PASMC apoptosis [31]. Therefore, hypoxia-HIF signaling 
is a potential therapeutic target to treat PAH, and several in vivo studies have demonstrated 
this [30–32].
5. Hypoxia and alveolar epithelial-to-mesenchymal transition (EMT)
Several groups have studied the role of hypoxia in disease progression and pathogenesis of 
ILDs such as pulmonary fibrosis [33, 34]. Activated myofibroblasts play an important role 
in the production of collagen and ECM proteins during pulmonary fibrosis. The source of 
these myofibroblasts are numerous, which include resident stromal fibroblasts, bone mar-
row-derived fibroblasts, and mesenchymal transition of epithelial and ECs [33]. Epithelial-to-
mesenchymal transition (EMT) is a cellular process during which epithelial cells lose many of 
their epithelial characteristics such as cell-cell interaction and apicobasal polarity and acquire 
properties typical to mesenchymal cells. EMT is driven by a cytokine, transforming growth 
factor-β1 (TGF-β1) and is characterized by changes in cell morphology and acquisition of 
mesenchymal markers including α-smooth muscle actin (α-SMA) and vimentin as well as 
loss of epithelial markers such as E-cadherin [33, 34]. Active TGF-β1 binds to its receptors 
(transmembrane serine-threonine kinase receptor I and II), which leads to a downstream acti-
vation of the transcription factor Smad, whose target genes include α-SMA and vimentin [33]. 
Increasing evidence over the years has highlighted the critical role of EMT in pathological con-
ditions such as fibrosis apart from its well-known involvement in tissue development during 
embryogenesis. Exposure to hypoxia during ALI could promote phenotypic changes in AEC 
consistent with EMT. In vitro studies on rat AEC cultured on semipermeable filters showed 
that prolonged hypoxic exposure (1.5% O2 for up to 12 days) induced profound changes 
in AEC phenotype consistent with EMT including change in cell morphology, decrease in 
transepithelial resistance and in the expression of epithelial markers such as zona occludens 
(ZO-1), E-cadherin, AQP-5, TTF-1, together with an increase in mesenchymal markers such 
as vimentin and α-SMA. Supporting this phenotypical switch, expression of transcription 
factors driving EMT such as SNAIL1, ZEB1 and TWIST1 increased after 2, 24 and 48 h of 
hypoxia, respectively. Hypoxia also induced expression and secretion of two EMT inducers 
TGF-β1 and connective tissue growth factor (CTGF) [35].
Similarly, Zhou et al. investigated the effect of hypoxia on the induction of EMT in AEC. 
Results from this study suggest that hypoxia induces EMT in transformed human, rat 
and mouse AEC lines, and freshly isolated rat type II AECs [36]. They also scrutinized 
the mechanism by which hypoxia induces EMT in AEC and showed the involvement of 
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hypoxia-induced mitochondrial ROS production and HIF-1α stabilization in TGF-β1 pro-
duction, resulting in EMT [37]. Treatment of cells with ROS scavenger Euk-134 or using 
mitochondria-deficient cells prevented hypoxia-induced EMT illustrating their impor-
tance in this cellular process. Moreover, although ROS is known to stabilize HIF-1α, their 
results showed that normoxic stabilization of HIF-1α failed to induce α-SMA expression, 
suggesting that HIF alone is not sufficient to induce EMT in AEC. Their data suggest that 
ROS and HIF-1α stabilization are upstream of TGF-β1 production in hypoxia-induced 
EMT in AEC. However, TGF-β1 can also increase ROS production and HIF-1α stabili-
zation. TGF-β1 can either directly activate NADPH (Nicotinamide adenine dinucleotide 
phosphate) oxidase or upregulate gene expression of Nox4 NADPH oxidase to generate 
ROS [38, 39]. TGF-β1 decreases mitochondrial complex IV activity resulting in disrup-
tion of mitochondrial membrane potential and ROS production [40]. TGF-β1 was reported 
to stabilize HIF-1α through selective inhibition of PHD2 (a HIF-1α prolyl hydroxylase) 
expression thus reducing HIF-1α prolyl hydroxylation leading to its stabilization [41]. 
Therefore, TGF-β1 and ROS/HIF may form a feedback loop to maintain a prolonged sig-
naling cascade initiated by either ROS/HIF or TGF-β1 leading to hypoxia-induced EMT 
in AECs [36].
In one interesting study, investigators evaluated the possible role of tissue hypoxia in the 
development of fibrotic lesions in lung fibrosis [42]. In this study, they used animal models 
of ALI/ARDS, in which severe inflammation progresses into the early (exudative) phase of 
ALI and sequentially fibrosis develops as the late (fibrotic) phase of ALI. They found intrigu-
ing effects of acute versus persistent hypoxia as seen in exudative and fibrotic phases of ALI, 
respectively. Acute hypoxia induced de novo Surfactant Protein-D (SP-D) expression in 
AECs followed by stabilization of HIF-1α expression [42]. Contrastingly, persistent hypoxia-
induced HIF-1α stabilization repressed SP-D expression and enhanced the mRNA levels of 
an EMT-driving transcription factor TWIST, but not SNAIL. This was accompanied by pheno-
typic switch in the AECs exposed to persistent hypoxia (72-h hypoxia for in vitro studies) as 
seen by decreased E-cadherin expression and enhanced vimentin expression. SP-D is mainly 
derived from alveolar epithelial cells and therefore loss of its expression during persistent 
hypoxia along with enhanced EMT transcription factor expression clearly indicates pheno-
typic switch of these alveolar epithelial cells to more proliferative phenotype contributing to 
lung fibrosis [42].
Endothelial-to-mesenchymal transition (EndMT) is similar to EMT, which is characterized by 
a loss of endothelial cell-cell junctions, the acquisition of migratory properties, and phenotypic 
switch involving loss of endothelial-specific markers such as CD31 and vascular endothelial 
(VE)-cadherin expression, and the acquisition of mesenchymal markers α-SMA, and vimentin 
[43]. EndMT also contributes to fibrosis. The role of EndMT in pulmonary fibrosis involves 
phenotypic switch in the pulmonary EC lining the pulmonary capillaries. Radiation-induced 
pulmonary fibrosis (RIPF) may involve hypoxia-mediated EndMT as an initial pathological 
insult leading to fibrosis [13]. Fleckenstein and colleagues have shown that radiation during 
thoracic radiotherapy for lung cancer induces tissue hypoxia, in part, due to enhanced oxygen 
consumption by Macrophages. These macrophages are activated because of radiation-induced 
reduction in blood perfusion in the lungs contributing to lung injury [44]. This suggests 
Hypoxia and Human Diseases234
that hypoxia plays a major role in the radiation-induced lung injury. Fleckenstein et al. also 
reported that hypoxia is important in triggering continuous production of fibrogenic cytokines 
and perpetuation of late lung tissue injury [44]. However, the precise mechanism by which 
hypoxia affects radiation-induced fibrosis remains elusive. EndMT of the pulmonary ECs was 
shown as a possible consequence of radiation-induced hypoxia resulting in lung fibrosis and 
injury by Choi et al. [43]. They investigated the reason behind fibrotic effects of radiation in a 
mouse model of RIPF and in in vitro studies on human pulmonary ECs. Since fibrosis is a long-
term event, their investigation aimed at elucidating the mechanisms behind the early damage 
to ECs by radiation and its link to the later observed fibrosis. Their results indicate ECs specifi-
cally expressing hypoxic marker, CA9, just prior to the substantial fibrogenesis. They went on 
to show that radiation-induced vascular hypoxia-triggered EndMT in vascular ECs, and in 
fact, this was observed prior to the onset of alveolar EMT and thus could be a trigger to EMT as 
well. Thus, EndMT contributed to chronic tissue fibrosis and targeting EndMT was speculated 
to be a potential therapeutic target to treat RIPF [43, 44].
In conclusion, current evidences suggest that the pathogenesis of human pulmonary fibrosis 
might involve the recruitment of fibroblasts derived from AECs through hypoxia-induced 
EMT as well as fibroblasts derived from pulmonary ECs through hypoxia-induced EndMT, 
apart from the bone marrow-derived precursors forming the fibrotic lesions. Thus, hypoxia 
could contribute to the formation of fibrotic lesions in the lung and hence the pathogenesis of 
pulmonary fibrosis (see Figure 1).
Figure 1. Summary of the effect of hypoxia on pulmonary tissue and vasculature. Hypoxia induces pulmonary edema 
by enhancing vascular permeability and decreasing the ability of alveolar fluid clearance. Hypoxia induces pulmonary 
vascular EndMT and alveolar EMT that result in myofibroblast proliferation ensuing pulmonary fibrosis. Hypoxia-
induced PAH is a result of enhanced proliferation and survival of PASMCs. ALI and PAH can eventually progress to 
pulmonary fibrosis.
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6. Hypoxia in lung injury resolution (fate of hypoxia as a  
consequence of pathological conditions)
While in the early stages of ALI, hypoxia plays a major role in the progression of lung injury, 
intriguingly in chronic pulmonary pathological conditions that ensue hypoxic milieu, and 
hypoxia has also been found to be involved in enhancing injury resolution. Studies indicate 
a protective and anti-inflammatory role of HIFs such as HIF-1α in lung protection dur-
ing the early exudative phase of ALI [45–47]. As mentioned above, hypoxia inactivates 
PHDs and stabilizes HIF-1α [45–47]. During the acute stage of ALI, inflammation, includ-
ing enhanced neutrophil activity within the alveoli, leads to an increased alveolar edema 
and decreased alveolar gaseous exchange capacity. HIF stabilization has been shown to 
have anti-inflammatory role in conditions like intestinal inflammation. The protective role 
of HIF activators in the treatment of inflammatory bowel disease or ischemia and reperfu-
sion injury of several organs has been shown in several studies [48–50]. Interestingly, Eckle 
et al. showed the beneficial role of normoxic HIF1A stabilization in lung protection during 
ALI, where HIF-dependent control of alveolar-epithelial glucose metabolism function as 
an endogenous feedback loop to dampen lung inflammation [51]. In vivo HIF-1α increased 
glycolysis, lactate production and glucose flux rates in alveolar epithelium. Overall, this 
normoxic stabilization of HIF-1α in alveolar epithelium increased glycolytic capacity and 
TCA flux thus optimizing mitochondrial respiration to enhance ATP production. This HIF-
dependent protection of mitochondrial function in ALI not only enhanced ATP production 
but also concomitantly prevented ROS accumulation and lung inflammation [51]. Hence, 
the role of hypoxia and subsequent HIF stabilization in reducing inflammation is prominent 
in resolution of ALI.
6.1. Hypoxia and adenosine signaling in lung injury resolution
Emigration of polymorphonucleated neutrophils (PMNs) through the endothelial barrier in 
an injured lung creates a potential for vascular fluid leakage leading to edema and decreased 
oxygenation [52]. The vascular endothelial adaptations to hypoxia include enhanced extracel-
lular adenosine production during limited oxygen availability. In the vascular ECs, hypoxia 
induces enhanced expression of surface ectonucleotidases, CD39 that converts ATP/ADP to 
AMP (ectoapyrase), as well as CD73 that is involved in phosphohydrolysis of AMP to ade-
nosine thus forming the source for extracellular adenosine production [52]. This enhanced 
extracellular adenosine can then signal through four different G-protein-coupled adenosine 
receptors, all of which are present on vascular endothelia thus enhancing adenosine signal-
ing that is implicated in tissue protection in different models of injury including ALI. Several 
studies, notably couple of them from Eltzschig, H.K., et al. [52, 53], have shown the role of 
extracellular adenosine and its signaling in attenuating hypoxia-induced vascular leakage. 
They also showed that the source of ATP in hypoxic milieu is the PMNs. Hypoxia induces the 
production of ATP by PMNs, however, the exact mechanism by which ATP is produced still 
needs to be explored. This ATP is then phosphohydrolyzed as mentioned above to produce 
extracellular adenosine [53]. Enhanced adenosine concentrations activate adenosine recep-
tor, (AdoRA
2A
/A2B on ECs, which when activated increases intracellular cyclic AMP (cAMP) 
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and activates protein kinase A (PKA) to induce resealing of the endothelial-barrier [54]. 
The  resealing of  endothelial-barrier during PMN transmigration was obviated by inhibition 
of cAMP formation. This resealing effect is mediated by PKA-induced phosphorylation of 
vasodilator-stimulated phosphoprotein, a protein responsible for changes in the geometry of 
actin filaments and distribution of junctional proteins as a result affecting the characteristics 
of junctional proteins and increasing barrier function [54]. Intriguingly, adenosine not only 
activates the endothelial A2B receptor, but also neutrophil A2 adenosine receptor which has been shown to play an important role in limitation and termination of PMN mediated sys-
temic inflammatory responses. Few others have also demonstrated that PMN A
2
 adenosine 
receptor stimulation decreased leukocyte adherence and transmigration which might con-
tribute to attenuated vascular leak associated with leukocyte accumulation [53–55]. Thus, 
hypoxia-induced adenosine signaling in vascular ECs and PMNs contributes to decreased 
vascular leak and inflammation, both of which are beneficial in inflammatory conditions such 
as ALI (see Figure 2).
When adenosine signaling was inhibited in transgenic mice with targeted disruption of CD73 
that were subjected to hypoxia, fulminant vascular leakage, associated with severe edema 
Figure 2. Hypoxia and adenosine signaling in the lungs. Hypoxia-induced extracellular adenosine production 
acts through adenosine receptors on ECs to enhance intracellular cAMP and PKA production. PKA catalyzes the 
phosphorylation of VASP, which integrates into stress fibers and helps seal the endothelial barrier by enhancing 
expression of AJs, TJs and also focal adhesion. PKA also enhances HIF-1A expression, which translocates into nucleus 
and enhances adenosine receptor transcription. Extracellular adenosine also acts on A2-receptors on PMNs and prevents 
their adhesion, rolling and infiltration into lung tissue. Thus, hypoxia-induced extracellular adenosine seals endothelial 
junctions, prevents PMN infiltration and protects lung tissue by preventing alveolar edema accumulation. PKA, protein 
kinase-A; PMN-polymorphonuclear neutrophils; ATP, adenosine triphosphate; AMP, adenosine monophosphate; A2bR, adenosine 2b receptor; cAMP, cyclic AMP; VASP, vasodilator-stimulated phosphoprotein; AJ, adherent junction; TJ, 
tight junction and ECM, extracellular matrix.
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and inflammation was seen [56]. Recently, studies have shown three other mechanisms by 
which hypoxia enhances extracellular adenosine levels, including hypoxia-mediated repres-
sion of the equilibrative nucleoside transporters (ENT-1 and ENT-2) that are responsible for 
 adenosine transport across the membrane into the cytoplasm; HIF-1α mediated inhibition of 
intracellular adenosine kinase that converts intracellular adenosine to AMP and transcrip-
tional induction of AdoRA2B receptor [57]. These studies indicate the protective role of ade-nosine signaling during hypoxia, especially in the pulmonary tissue [37]. On the other hand, 
chronically increased adenosine levels are detrimental as seen in pathological conditions, 
such as asthma and chronic obstructive pulmonary disease (COPD), and they also correlate 
with degree of inflammation in COPD. In order to regulate excessive adenosine signaling, 
chronic exposure to hypoxia eventually induces endothelial CD26 and extracellular adenos-
ine deaminase (ADA). CD26 on EC surface acts as the ADA-complexing protein and localizes 
ADA accumulation on EC surface limiting extracellular adenosine accumulation during pro-
longed hypoxia [55].
6.2. Hypoxia and lung inflammation
Uncontrolled inflammation is one of the major players in ALI and suppression of inflamma-
tion is beneficial for injury resolution [58, 59]. Interestingly, as mentioned above, hypoxia-
induced, HIF-1–mediated enhanced expression of Adenosine A
2
 receptor on different types 
of immune cells, along with enhanced extracellular adenosine levels, which activate these 
receptors, are responsible for anti-inflammatory and tissue-protecting effects of hypoxia [58, 
59]. This anti-inflammatory effect is attributed to elevated intracellular cAMP levels through 
activation of adenylyl cyclase. Even pharmacological immunosuppressive molecules, such 
as catecholamines, neuropeptides, histamine and prostaglandins are known to have their 
effects through elevation of cAMP levels [59]. Therefore, this extracellular adenosine serves 
to report excessive collateral immune damage and prevents further damage by suppress-
ing-activated immune cells. Adenosine triggers high-affinity A
2A
 adenosine receptors on 
activated immune cells resulting in enhanced intracellular cAMP levels to suppress these 
immune cells. Few studies also show that hypoxia inhibits adenosine kinase, an enzyme 
responsible for re-phosphorylation of adenosine to AMP, to maximize the anti-inflammatory 
effect [60].
6.3. Adenosine receptors in inflammation
Adenosine receptors are a family of heptahelical transmembrane G-protein-coupled puri-
nergic receptors that are classified into four types based on the potency of agonists with 
respect to the intracellular production of cAMP [37]. They are A1
,
 A
2A,
 A2B and A3 receptors. Extracellular agonists signal through these G protein receptors and can either stimulate (Gs) 
or inhibit (Gi) adenylyl cyclase, an enzyme that catalyzes the formation of cAMP. Cloning 
experiments show that high-affinity A
2A
 and low-affinity A2B receptors activate adenylyl cyclase (Gs) enhancing the levels of intracellular cAMP, whereas high-affinity A1 and low-
affinity A3 receptors inhibit (Gi) adenylyl cyclase [37].
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6.4. Hypoxia induced adenosine signaling in individual immune cells
a. Polymorphonuclear Leukocytes (PML): Pathological stimulation of inflammation can result in 
deleterious nonspecific PML bactericidal effector functions directed towards hosts’ healthy 
tissue resulting in extensive collateral damage [54]. PMN toxic effects on microvascular 
endothelium are more prominent as they attach to ECs, easily because they use the same 
recepvtors (CR3, CD11b/CD18) that ensure PML attachment to pathogenic microorganisms 
[54]. Hypoxia-induced extracellular adenosine acts through adenosine receptor (high affin-
ity A1 and A2 receptors) to mediate its anti-inflammatory effect. However, since both A1 
and A2 are high affinity receptors, the overall effects of adenosine on PML might depend 
on the interplay between them and their expression on PML [61]. Studies show that the 
anti-inflammatory effects of A
2A
 receptor are to a certain extent prevented by A1 recep-
tor, on the other hand, deleterious effects such as chemotaxis, adhesion and oxygen radi-
cal production stimulated by A1 were inhibited by A
2A
 [61, 62]. Overall, hypoxia-induced extracellular adenosine may protect the microvascular endothelium from PML by inhibit-
ing the expression of β2-integrins and adhesion, ROS production, TNF-α production and 
degranulation, all of which without compromising the bactericidal function of PML such 
as production of bactericidal toxins and complement receptor type-3–mediated phagocy-
tosis of bacteria [54, 63].
b. Mononuclear phagocytes and dendritic cells: In macrophages, activation of A1 receptor is 
stimulatory, while A2 receptor activation is inhibitory [54]. A
2A
 receptor activation in 
lipopolysaccharide (LPS)-stimulated macrophages was associated with the inhibition of 
IL-12 production but enhanced IL-10 secretion. In LPS-stimulated dendritic cells, adenos-
ine enhanced A
2A
 receptor expression and intracellular cyclic AMP production along with 
inhibition of IL-12 production. In dendritic cells, except adenosine, other cAMP-elevating 
agents increase IL-10 and lower expression of MHC type II [64]. However, adenosine-medi-
ated A
2A
 activation decreases the capacity of maturing dendritic cells to induce T-helper 
(Th1) polarization of native CD4+ T-lymphocytes (possible anti-inflammatory effect). Upon 
LPS-induced differentiation of dendritic cells, A
2A
 activation favors production of CCL17 
over CXCL10 chemokines [65]. Overall, these studies suggest that extracellular adenos-
ine stimulation of adenosine receptors on antigen-presenting cells (macrophages and 
dendritic cells) might play an important role in the downregulation and polarization of 
immune response, modulation of MHC class I and II expression, and/or decrease in IL-12 
and increase in IL-10 or IL-4 production to favor the initiation of a Th2 response over a Th1 
response. This effect of adenosine on innate and adoptive immune system plays a crucial 
role in the modulation of inflammatory response [54, 64–66].
c. Thymocytes: The microenvironment of thymocytes is hypoxic even under normal physi-
ological condition when compared to other lymphoid and non-lymphoid tissues [54]. Thus, 
the thymic environment favors increased adenosine levels and its signaling. Patients with 
severe combined immunodeficiency were found to be ADA deficient (enzyme responsible 
for decreased adenosine levels), where ADA deficient patients had developmental defects 
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in T- and B-cells [67, 68]. This enhanced extracellular adenosine signals through A
2A
 recep-
tor and induces apoptosis in a subset of immature thymocytes through its cAMP elevat-
ing effects. In peripheral T-cells, activation of extracellular adenosine-mediated A
2A
 receptor 
inhibits TCR-triggered IL-2 receptor upregulation, thereby inhibiting T-cell proliferation [69]. 
Other effects of adenosine signaling in CD8+ cytotoxic T-lymphocytes include  inhibition of 
inflammatory cytokine production, lethal hit delivery by granule exocyotosis, as well as FasL 
mRNA upregulation. It is interesting to note that in human blood peripheral leukocytes, 
more CD4+ than CD8+ T-cells express A
2A
 receptor, but on activation of T-cells increased A
2A
 
receptor expression is predominantly observed in CD8+ T-cells. These studies suggest the 
variable expression of A
2A
 receptors on T-cell subset and how they favor the production of 
anti-inflammatory cytokines over inflammatory cytokines. Compared to T-lymphocytes, not 
much is known about the effects of A
2A
 receptor signaling in B-cell development, activation, 
antibody-production and class switching, and cytokine secretion [70].
However, it is very important to note that all the above mentioned effects of extracellular ade-
nosine on immune cells were mostly observed in pharmacological experiments and is yet to be 
explored whether there are sufficient levels of extracellular adenosine in vivo to signal through 
A
2A
 receptor on immune cells. So far, there is no evidence of physiological downregulation of 
immune cells by extracellular adenosine in vivo. However, hypoxia-induced extracellular ade-
nosine may have anti-inflammatory effects even in in vivo similar to in vitro studies [67, 71, 72].
7. Conclusions and future directions
Hypoxia, either as a consequence of the pathological condition during ILDs or as an etiology 
for ILDs has several roles in modulating the severity of the disease condition. Most of the effects 
of hypoxia are regulated through HIFs. Interestingly, stabilization of HIFs at various stages of 
lung injury can have different consequences either favoring injury resolution or worsening the 
condition. This complicates to provide a potential therapeutic target against HIFs to treat ILDs. 
Targeting hypoxia signaling was speculated to have therapeutic importance in inflammatory 
and ischemic conditions, such as inflammatory bowel disease, myocardial ischemic-reperfu-
sion injury, ALI and so on. However, most of the clinical trials for drug discovery examined 
HIF inhibitors in the context of cancer treatment. Some of the examples include pharmaco-
logical HIF inhibitors such as dutasteride152 (ClinicalTrials.gov identifier: NCT00880672), 
topotecan153 (ClinicalTrials.gov identifier: NCT00117013), PX-478 (ClinicalTrials.gov identi-
fier: NCT00522652) or digoxin13 (ClinicalTrials.gov identifier: NCT01763931) or the antisense 
oligonucleotide HIF inhibitor EZN-2968 (ClinicalTrials.gov identifier: NCT01120288). Apart 
from HIF inhibitors, HIF-stabilizing agents such as PHD inhibitors are also being studied as 
potential therapeutic targets in conditions where HIF stabilization is beneficial, such as, con-
ditions which require enhanced angiogenesis (HIF activates VEGF and enhances angiogen-
esis) like bronchopulmonary dysplasia, a chronic disease effecting preterm neonates in which 
enhanced angiogenesis improves lung growth and function. Favoring the plethora of evidence 
from preclinical studies, in future, we can expect more clinical trials targeting PHD-HIF path-
way as a potential therapy for ILDs and several other ischemic conditions.
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